|Page (1) of 1 - 09/19/17||email article||print page|
(September 19, 2017)
DUBLIN, Sept. 19, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will present a corporate overview at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26, 2017 at 9:10 a.m. ET. The conference will be held September 25 - 27 at the Intercontinental New York Barclay Hotel.
A live broadcast will be available by visiting the Investor Relations section of Theravance Biopharma's website at www.theravance.com, under the Presentations & Events tab. Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software.
About Theravance Biopharma
Theravance Biopharma, Inc. is a diversified biopharmaceutical company with the core purpose of creating medicines that help improve the lives of patients suffering from serious illness.
Our pipeline of internally discovered product candidates includes potential best-in-class medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. VIBATIV® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist ("LAMA") being developed as a potential once-daily, nebulized treatment for chronic obstructive pulmonary disease ("COPD"). Our neprilysin ("NEP") inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of major cardiovascular and renal diseases, including acute and chronic heart failure, hypertension and chronic kidney diseases such as diabetic nephropathy. Our research efforts are focused in the areas of inflammation and immunology, with the goal of designing medicines that provide targeted drug delivery to tissues in the lung and gastrointestinal tract in order to maximize patient benefit and minimize risk. The first program to emerge from this research is designed to develop intestinally restricted pan-Janus kinase ("JAK") inhibitors for the treatment of a range of inflammatory intestinal diseases.
In addition, we have an economic interest in future payments that may be made by Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain drug development programs, including Trelegy Ellipta (the combination of fluticasone furoate, umeclidinium, and vilanterol in a single ELLIPTA® inhaler, previously referred to as the Closed Triple), currently approved in the US for the treatment of appropriate COPD patients and in development for the treatment of COPD in several other countries. The product is also currently in development for the treatment of asthma.
For more information, please visit www.theravance.com.
THERAVANCE®, the Cross/Star logo, and VIBATIV® are registered trademarks of the Theravance Biopharma group of companies.
Head of Investor Relations
View original content with multimedia:http://www.prnewswire.com/news-releases/theravance-biopharma-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-300521289.html
SOURCE Theravance Biopharma, Inc.
Copyright 2014 PR Newswire. All Rights Reserved
Related Keywords:Pro AV, Management, Presentors, Business Issues, Presentation, Corporate/Company, Events, USA, Inc., Medicine, Disease, healthcare, medical technologists, Surgery, Children, Other,
Related Sites: Digital Producer , Audio Video Producer , Presentation Master , Oceania , DMN Newswire , VideoBasedTutorials , HTN - Health Technology Net
Related Newsletter: DMN Newsletter , CMN Newsletter , KNews Newsletter , Tutorial Finder , Review Seeker , DMN Newswire Newsletter